The Australian Immunisation Handbook 10th Edition

8 May 2013

Page last updated: 01 August 2017

8 May 2013

3.3 Groups with special vaccination requirements

3.3.5 Vaccination of persons with bleeding disorders

The first paragraph under this heading (page 168) should read as follows:

Persons who are receiving anticoagulant therapy may develop haematomas in IM injection sites. The length of anticoagulant therapy should be clarified and immunisation delayed if therapy is going to be of short-term duration. Unless warfarin or low molecular weight heparin (LMWH) doses are known to be stable, persons receiving anticoagulants should have appropriate levels checked before vaccine administration, if possible. Intramuscular injections should be deferred if the INR is >3.0 (warfarin) or the anti-Xa (LMWH) level 4 hours post dose is >0.5 Units/mL.